

<p>FORM PTO-1449 (Rev. 2-32)</p> <p>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(Use several sheets if necessary)</p>	<p>U.S. Department of Commerce Patent and Trademark Office</p>	<p>Atty. Docket No. 02-742-N (400/142)</p>	<p>Serial No. 10/758,155</p>
		<p>Applicant: McSwiggen et al.</p>	
		<p>Filing Date: January 12, 2004</p>	<p>Group:</p>

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
AB	1.	02/094185 (PCT/US02/15876)	11/28/02	WO (Beigelman et al.)				
	2.	02/096927 (PCT/US02/17674)	12/05/02	WO (Pavco et al.)				
	3.	03/47518	06/12/03	WO (Wang et al.)				
	4.	03/070910 (PCT/US03/05022)	08/28/03	WO (Beigelman et al.)				
	5.	03/074654 (PCT/US03/05028)	09/12/03	WO (McSwiggen et al.)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

AB	6.	Genbank Accession No. AF020393 (11/02/97)
	7.	Genbank Accession No. AF022375 (10/07/98)
	8.	Genbank Accession No. AF024710 (05/17/99)
	9.	Genbank Accession No. AF035121 (12/02/97)
	10.	Genbank Accession No. AF063657 (12/06/04)
	11.	Genbank Accession No. AF063658 (05/16/98)

<p>EXAMINER /Amy Bowman/</p>	<p>DATE CONSIDERED 12/07/2006</p>
-----------------------------------	--

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-742-N (400/142)	Serial No. 10/758,155
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: January 12, 2004	Group:

AB	12.	Genbank Accession No. AF092125 (01/07/2000)
	13.	Genbank Accession No. AF092126 (01/07/2000)
	14.	Genbank Accession No. AF092127(01/07/2000)
	15.	Genbank Accession No. AF095785 (05/29/2002)
	16.	Genbank Accession No. AF098331 (02/08/99)
	17.	Genbank Accession No. AF437895 (11/05/2001)
	18.	Genbank Accession No. AF468110 (02/20/2002)
	19.	Genbank Accession No. AF486837(04/03/2002)
	20.	Genbank Accession No. AH006909 (10/07/99)
	21.	Genbank Accession No. AJ000185 (04/15/2005)
	22.	Genbank Accession No. AJ010438 (01/15/99)
	23.	Genbank Accession No. AY047581 (09/03/2001)
	24.	Genbank Accession No. D89630 (02/07/99)
	25.	Genbank Accession No. E13256 (11/05/2005)
	26.	Genbank Accession No. E13332 (11/05/2005)
	27.	Genbank Accession No. E14000 (11/05/2005)
	28.	Genbank Accession No. E14233 (11/05/2005)
	29.	Genbank Accession No. E15156 (11/05/2005)
✓	30.	Genbank Accession No. E15157 (11/05/2005)

EXAMINER /Amy Bowman/	DATE CONSIDERED 12/07/2006
---------------------------------	--------------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		02-742-N (400/142)	10/758,155
		Applicant:	
		McSwiggen et al.	
		Filing Date:	Group:
		January 12, 2004	

AB	31.	Genbank Accession No. NM_002019 (04/09/2006)
	32.	Genbank Accession No. NM_002020 (06/12/2006)
	33.	Genbank Accession No. NM_002253 (06/18/2006)
	34.	Genbank Accession No. NM_003376 (06/25/2006)
	35.	Genbank Accession No. NM_003377 (03/04/2006)
	36.	Genbank Accession No. NM_004469 (04/16/2006)
	37.	Genbank Accession No. NM_005429 (06/12/2006)
	38.	Genbank Accession No. U01134 (02/02/94)
	39.	Genbank Accession No. X62568 (07/30/96)
	40.	Genbank Accession No. X94216 (04/18/2005)
	41.	Genbank Accession No. Y08736 (10/27/97)
↓	42.	Strauss, Evelyn, "Molecular Biology: Candidate 'Gene Silencers' Found" <u>Molecular Biology</u> , 286: 5441, p.886 (1999)

EXAMINER	/Amy Bowman/	DATE CONSIDERED	12/07/2006
----------	--------------	-----------------	------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-742-N (400/142)	Serial No. 10/758,155
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: January 12, 2004	Group:

AB	*	Lin et al., "A Novel mRNA-cRNA Interference Phenomenon for Silencing bcl-2 Expression in Human LNCaP Cells," <i>Biochemical and Biophysical Research Communications</i> , 281, 639-644 (2001)
	*	Lin et al., "Policing Rogue Genes", <i>Nature</i> 402:128-129 (1999)
	*	Lisiewicz et al., "Inhibition of Human Immunodeficiency Virus Type 1 Replication by Regulated Expression of a Polymeric Tat Activation Response RNA Decoy as a Strategy for Gene Therapy in AIDS," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 90:8000-8004 (1993)
	*	Liu et al., "Cationic Liposome-mediated Intravenous Gene Delivery," <i>J. Biol. Chem.</i> 270(42):24864-24870 (1995)
	*	Loakes, "The Applications of Universal DNA Base Analogues," <i>Nucleic Acids Research</i> 29:2437-2447 (2001)
	*	Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach. 2. Generation of Covalently Closed, Double-Stranded Cyclic HIV-1 TAR RNA Analogs with High Tat-Binding Affinity," <i>Nucleic Acids Research</i> 21:2585-2589 (1993)
	*	Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach," <i>Biochemistry</i> 32:1751-1758 (1993)
	*	Martinez et al., "Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi," <i>Cell</i> 110:563-574 (2002)
	*	Maurer et al., "Lipid-based systems for the intracellular delivery of genetic drugs," <i>Molecular Membrane Biology</i> 16:129-140 (1999)
	*	McCurdy et al., "Deoxyoligonucleotides with Inverted Polarity: Synthesis and Use in Triple-Helix Formation" <i>Nucleosides & Nucleotides</i> 10:287-290 (1991)
	*	McGarry and Lindquist, "Inhibition of heat shock protein synthesis by heat-inducible antisense RNA," <i>Proc. Natl. Acad. Sci. USA</i> 83:399-403 (1986)
✓	*	McLaren et al., "Vascular Endothelial Growth Factor (VEGF) Concentrations are Elevated in Peritoneal Fluid of Women with Endometriosis," <i>Human Reproduction</i> 11:220-223 (1996)

EXAMINER /Amy Bowman/	DATE CONSIDERED 12/07/2006
---------------------------------	--------------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-742-N (400/142)	Serial No. 10/758,155
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al. Filing Date: January 12, 2004	

AB	*	Ohkawa et al., "Activities of HIV-RNA Targeted Ribozymes Transcribed From a 'Shot-Gun' Type Ribozyme-trimming Plasmid," <i>Nucleic Acids Symp. Ser.</i> 27:15-16 (1992)
	*	Ohno-Matsui, et al., "Inducible Expression of Vascular Endothelial Growth Factor in Adult Mice Causes Severe Proliferative Retinopathy and Retinal Detachment," <i>Animal Models</i> from the Departments of Ophthalmology and Neuroscience and Molecular Biology and Genetics, <i>Am. J. Pathology</i> , 160, 711-719 (2002)
	*	Ojwang et al., "Inhibition of Human Immunodeficiency Virus Type 1 Expression by a Hairpin Ribozyme," <i>Proc. Natl. Acad. Sci. USA</i> 89:10802-10806 (1992)
	*	Oku et al., "Real-time analysis of liposomal trafficking in tumor-bearing mice by use of positron emission tomography," <i>Biochimica et Biophysica Acta</i> 1238:86-90 (1995)
	*	Ono et al., "DNA Triplex Formation of Oligonucleotide Analogues Consisting of Linker Groups and Octamer Segments That Have Opposite Sugar-Phosphate Backbone Polarities," <i>Biochemistry</i> 30:9914-9921 (1991)
	*	O'Reilly et al., "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," <i>Cell</i> 79:315-328 (1994)
	*	Orgis et al., "DNA/polyethylenimine transfection particles: Influence of ligands, polymer size, and PEGylation on internalization and gene expression," <i>AAPS PharmSci.</i> , 3 (3) article 21 (http://www.pharmsci.org) p. 1- 11 (2001)
	*	Ormerod et al., "Effects of Altering the Eicosanoid Precursor Pool on Neovascularization and Inflammation in the Alkali-burned Rabbit Cornea," <i>American Journal of Pathology</i> 137:1243-1252 (1990)
	*	Pal-Bhadra et al., "Heterochromatic Silencing and HP1 Localization in <i>Drosophila</i> Are Dependent on the RNAi Machinery," <i>Science</i> , 303, 669-672 (2004)
	*	Pandey et al., "Role of B61, the Ligand for the Eck Receptor Tyrosine Kinase, in TNF- α -Induced Angiogenesis," <i>Science</i> 268:567-569 (1995)
✓	*	Pardridge et al., "Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo," <i>Proc. Natl. Acad. Sci. USA</i> 92:5592-5596 (1995)

EXAMINER /Amy Bowman/	DATE CONSIDERED 12/07/2006
---------------------------------	--------------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. 02-742-N (400/142)	Serial No. 10/758,155
	Applicant: McSwiggen et al.	
	Filing Date: January 12, 2004	Group:

AB	*	Usman et al., "Automated Chemical Synthesis of Long Oligoribonucleotides Using 2'-O-Silylated Ribonucleoside 3'-O-Phosphoramidites on a Controlled-Pore Glass Support: Synthesis of a 43-Nucleotide Sequence Similar to the 3'-Half Molecule of an Escherichia coli Formylmethionine tRNA," J. Am. Chem. Soc. 109:7845-7854 (1987)
	*	Usman et al., "Chemical modification of hammerhead ribozymes: activity and nuclease resistance," Nucleic Acids Symposium Series 31:163-164 (1994)
	*	Ventura et al., "Activation of HIV-Specific Ribozyme Activity by Self-Cleavage," Nucleic Acids Research 21:3249-3255 (1993)
	*	Verdel et al., "RNAi-Mediated Targeting of Heterochromatin by the RITS Complex, Science, 303, 672-676 (2004)
	*	Verma and Eckstein, "Modified Oligonucleotides: Synthesis and Strategy for Users," Annu. Rev. Biochem. 67:99-134 (1998)
	*	Volpe et al., "Regulation of Heterochromatic Silencing and Histone H3 Lysine-9 Methylation by RNAi," Science 297:1833-1837 (2002)
	*	Waterhouse, et al. "Virus Resistance and gene Silencing in Plants Can Be Induced by Simultaneous Expression of Sense and Antisense RNA" Proc. Natl. Acad. Sci. USA 99:13959-13964 (1998)
	*	Weckbecker et al., "Intradermal angiogenesis in nude mice induced by human tumor cells or b-FGF," Angiogenesis Key Principles-Science-Technology-Medicine pp296-301 (1992)
	*	Weerasinghe et al., "Resistance to Human Immunodeficiency Virus Type 1 (HIV-1) Infection in Human CD4+ Lymphocyte-Derived Cell Lines Conferred by Using Retroviral Vectors Expressing an HIV-1 RNA-Specific Ribozyme," Journal of Virology 65:5531-5534 (1994)
	*	Wellstein and Czubayko, "Inhibition of Fibroblast Growth Factors," Breast Cancer Research and Treatment 38:109-119 (1996)
V	*	Wianny and Zernicka-Goetz et al., "Specific Interference with Gene Function by Double-Stranded RNA in Early Mouse Development," Nature Cell Biology 2:70-75 (2000)

EXAMINER /Amy Bowman/	DATE CONSIDERED 12/07/2006
------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.


11-2-06

PTO/SB/088 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution for form 1449/PTO  THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
Application No.		10/758,155	
Filing Date:		January 12, 2004	
First Named Inventor		McSwiggen et al.	
Art Unit		1635	
Examiner Name		ASHEN, Jon Benjamin	
Attorney Docket Number		02-742-N (400/141)	
Sheet	1	of	1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
AB ↓	A	US-5,587,471	12-1996	Cook et al.	
	B	US-5,916,763	06-1999	Williams et al.	
	C	US-6,710,174	03-23-2004	Bennett et al.	
	D	US-2004/0018176	01-2004	Tolentino et al.	
	E	US-2004/0209832	10-2004	McSwiggen et al.	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
AB ↓	*	Caplen, Nathan, "RNAi as a gene therapy approach," <i>Expert Opin. Biol. Ther.</i> 3(4):575-586 (2003)			
	*	Hammond, et al., "Post-transcriptional Gene Silencing by Double-Stranded RNA," <i>Nature Reviews</i> , 2:110-119 (2001)			
	*	Mahato et al., "Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA," <i>Expert Opin. Drug Deliv.</i> , 2(1):3-28 (2005)			
	*	Scherer et al., "Approaches for the sequence-specific knockdown of mRNA," <i>Nature Biotechnology</i> , 21:12, 1457-1465 (2003)			
	*	Schmidt et al., "Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure," <i>Nucleic Acids Research</i> 24:573-581 (1996)			
	*	Vickers et al., "Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents," <i>The Journal of Biological Chemistry</i> , 278:9, 7108-7118 (2003)			
	*	Zhang et al., "Targeted Gene Silencing by Small Interfering RNA-based Knock-Down Technology," <i>Current Pharmaceutical Biotechnology</i> , 5, 1-7 (2004)			
Examiner Signature	/Amy Bowman/			Date Considered	12/07/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.